领导团队

执行官

tony j. hunt

Chief Executive Officer

Tony J. Hunt joined Repligen in May 2014 and currently serves as Chief Executive Officer (“CEO”) and has served on the Board since May 2015. Before being named CEO in May 2015, Mr. Hunt served as Chief Operating Officer (“COO”), overseeing commercial and manufacturing operations. Prior to joining Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. Mr. Hunt joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt serves on the board of directors of 908 Devices Inc., a publicly traded company, Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. 

Olivier Loeillot

President, Chief Commercial Officer

Olivier Loeillot joined Repligen in October 2023 as President and Chief Commercial Officer (“CCO”), where he has responsibility for driving the Company’s commercial strategy and expanding the market impact of Repligen’s business units. Prior to joining Repligen, Mr. Loeillot was Chief Executive Officer (“CEO”) at Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets. Mr Loeillot previously served a combined 12 years with Cytiva (a Danaher company and previously GE Healthcare Life Sciences). While at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Mr. Loeillot was also instrumental in building and leading the Enterprise Solutions business, managing the Bioprocess Asia business in Singapore, and directing the Genomics and Cellular Research division. Prior to Cytiva, Mr. Loeillot served a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. He also acted as Vice President of Sales for Lonza AG’s custom manufacturing business and led the Microbial Biopharmaceuticals group. Mr. Loeillot earned his M.S. in Chemistry in 1993 from the European High Institute of Chemistry of Strasbourg, France, and later completed a M.B.A. program at CESMA Business School of EM Lyon.

Jason K. Garland

首席财务官

Jason K. Garland joined Repligen in September 2023 as Chief Financial Officer (“CFO”), where he oversees financial operations for the Company. In this position, he holds responsibility for all corporate finance and audit functions, capital markets and M&A transactions, financial planning and analysis, budgeting and risk management, information technology and investor relations. Before joining Repligen, Mr. Garland was with Integer Holdings Corporation (“Integer”), a medical device outsource manufacturer, where he served for nearly five years as Executive Vice President and CFO, and assumed executive sponsorship of the company’s business process excellence initiative focused on standardizing and optimizing all non-manufacturing processes. Prior to his role with Integer, Mr. Garland spent three years as Vice President and CFO for the global sales and supply divisions of Tiffany & Co., following nearly 20 years in various roles of increasing responsibility at General Electric Corporation (“GE”). His rotations and achievements at GE culminated in several leadership positions including his role as CFO for GE Industrial Solutions, then a multi-billion dollar business with over 40 manufacturing sites. Mr. Garland serves on the board of directors at Acutus Medical, a publicly traded medical device company. He holds a B.S. in Chemical Engineering from the University of New Hampshire and is Lean Six Sigma Black Belt certified.

jim bylund

Chief Operating Officer

James R. Bylund joined Repligen in March 2020 and currently serves as Chief Operating Officer (“COO”) and principal operating officer. Before being named COO in January 2022, Mr. Bylund acted as Senior Vice President, Global Operations and Information Technology. Before joining Repligen, Mr. Bylund worked in real estate at Inspire Development in Austin, Texas between March 2019 and March 2020. Prior to this, Mr. Bylund spent 10 years with Thermo Fisher Scientific in various leadership roles including Vice President and General Manager of the Single Use Technologies Business Unit, and Vice President of Global Operations for the Bioproduction Division. Mr. Bylund also worked for Fiserv (nine years) and Eli Lilly and Company (seven years) in a variety of leadership roles. He has significant experience in managing multiple operating sites across the globe and scaling operations to meet rapidly growing demand. Mr. Bylund is a passionate proponent of continuous improvement and has consistently demonstrated the ability to assemble and grow highly effective teams. He holds a B.S. in Accounting from Utah State University and earned his M.B.A. from Indiana University.

christine gebski

Senior Vice President, Filtration and Chromatography

Christine Gebski joined Repligen in May 2015 and currently serves as Senior Vice President, Filtration and Chromatography where she oversees the general management and strategy of the Company’s upstream and downstream filtration and chromatography portfolios. Prior to joining Repligen, Ms. Gebski was head of the Chromatography Business Unit within the Bioproduction Division of Thermo Fisher Scientific and managed the Global Process Chromatography Applications and research and development (“R&D”) functions for 10 years. Before joining Thermo Fisher Scientific, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry, having held positions of increasing responsibility at Genzyme Corporation, Transkaryotic Therapeutics (acquired by Shire Pharmaceuticals) and EMD Pharmaceuticals. Ms. Gebski has significant experience in product development and commercialization, product life cycle management, downstream process development and engineering, technology transfer and validation across a variety of biological molecule classes and diagnostic reagents. She holds a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.

Ralf Kuriyel

高级副总裁,研发

Ralf Kuriyel joined Repligen in October 2016 and currently serves as Senior Vice President, R&D where he oversees the Company’s innovation programs, including the strategic integration of acquired technologies. Prior to joining Repligen, Mr. Kuriyel was Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation (“Pall”), whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. He is an inventor on multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques. Mr. Kuriyel received a B.S. and an M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and has completed coursework for the Tufts University Ph.D. program in Chemical Engineering. 

Tony J. Hunt joined Repligen in May 2014 and currently serves as Chief Executive Officer (“CEO”) and has served on the Board since May 2015. Before being named CEO in May 2015, Mr. Hunt served as Chief Operating Officer (“COO”), overseeing commercial and manufacturing operations. Prior to joining Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. Mr. Hunt joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt serves on the board of directors of 908 Devices Inc., a publicly traded company, Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. 

Olivier Loeillot joined Repligen in October 2023 as President and Chief Commercial Officer (“CCO”), where he has responsibility for driving the Company’s commercial strategy and expanding the market impact of Repligen’s business units. Prior to joining Repligen, Mr. Loeillot was Chief Executive Officer (“CEO”) at Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets. Mr Loeillot previously served a combined 12 years with Cytiva (a Danaher company and previously GE Healthcare Life Sciences). While at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Mr. Loeillot was also instrumental in building and leading the Enterprise Solutions business, managing the Bioprocess Asia business in Singapore, and directing the Genomics and Cellular Research division. Prior to Cytiva, Mr. Loeillot served a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. He also acted as Vice President of Sales for Lonza AG’s custom manufacturing business and led the Microbial Biopharmaceuticals group. Mr. Loeillot earned his M.S. in Chemistry in 1993 from the European High Institute of Chemistry of Strasbourg, France, and later completed a M.B.A. program at CESMA Business School of EM Lyon.

Jason K. Garland joined Repligen in September 2023 as Chief Financial Officer (“CFO”), where he oversees financial operations for the Company. In this position, he holds responsibility for all corporate finance and audit functions, capital markets and M&A transactions, financial planning and analysis, budgeting and risk management, information technology and investor relations. Before joining Repligen, Mr. Garland was with Integer Holdings Corporation (“Integer”), a medical device outsource manufacturer, where he served for nearly five years as Executive Vice President and CFO, and assumed executive sponsorship of the company’s business process excellence initiative focused on standardizing and optimizing all non-manufacturing processes. Prior to his role with Integer, Mr. Garland spent three years as Vice President and CFO for the global sales and supply divisions of Tiffany & Co., following nearly 20 years in various roles of increasing responsibility at General Electric Corporation (“GE”). His rotations and achievements at GE culminated in several leadership positions including his role as CFO for GE Industrial Solutions, then a multi-billion dollar business with over 40 manufacturing sites. Mr. Garland serves on the board of directors at Acutus Medical, a publicly traded medical device company. He holds a B.S. in Chemical Engineering from the University of New Hampshire and is Lean Six Sigma Black Belt certified.

James R. Bylund joined Repligen in March 2020 and currently serves as Chief Operating Officer (“COO”) and principal operating officer. Before being named COO in January 2022, Mr. Bylund acted as Senior Vice President, Global Operations and Information Technology. Before joining Repligen, Mr. Bylund worked in real estate at Inspire Development in Austin, Texas between March 2019 and March 2020. Prior to this, Mr. Bylund spent 10 years with Thermo Fisher Scientific in various leadership roles including Vice President and General Manager of the Single Use Technologies Business Unit, and Vice President of Global Operations for the Bioproduction Division. Mr. Bylund also worked for Fiserv (nine years) and Eli Lilly and Company (seven years) in a variety of leadership roles. He has significant experience in managing multiple operating sites across the globe and scaling operations to meet rapidly growing demand. Mr. Bylund is a passionate proponent of continuous improvement and has consistently demonstrated the ability to assemble and grow highly effective teams. He holds a B.S. in Accounting from Utah State University and earned his M.B.A. from Indiana University.

Christine Gebski joined Repligen in May 2015 and currently serves as Senior Vice President, Filtration and Chromatography where she oversees the general management and strategy of the Company’s upstream and downstream filtration and chromatography portfolios. Prior to joining Repligen, Ms. Gebski was head of the Chromatography Business Unit within the Bioproduction Division of Thermo Fisher Scientific and managed the Global Process Chromatography Applications and research and development (“R&D”) functions for 10 years. Before joining Thermo Fisher Scientific, Ms. Gebski was a Process Development Scientist for 15 years in the biotechnology industry, having held positions of increasing responsibility at Genzyme Corporation, Transkaryotic Therapeutics (acquired by Shire Pharmaceuticals) and EMD Pharmaceuticals. Ms. Gebski has significant experience in product development and commercialization, product life cycle management, downstream process development and engineering, technology transfer and validation across a variety of biological molecule classes and diagnostic reagents. She holds a B.S. in Biology from the University of Vermont and a M.S. in Biotechnology from the University of Massachusetts at Lowell.

Ralf Kuriyel joined Repligen in October 2016 and currently serves as Senior Vice President, R&D where he oversees the Company’s innovation programs, including the strategic integration of acquired technologies. Prior to joining Repligen, Mr. Kuriyel was Vice President of Applications for the single-use business unit within the Life Sciences division of Pall Corporation (“Pall”), whose acquisition by Danaher Corporation was completed in August 2015. At Pall, Mr. Kuriyel served as Vice President of R&D, Field Applications and Process Development Services from November 2014 to October 2016. In addition, Mr. Kuriyel served as Vice President, Applications R&D at Pall from November 2011 to November 2014. He is an inventor on multiple patents and has co-authored over 30 scientific publications on bioprocessing, including separations technologies, membrane separations methods, protein processing and enhanced microfiltration techniques. Mr. Kuriyel received a B.S. and an M.S. in Chemical Engineering from Rensselaer Polytechnic Institute and has completed coursework for the Tufts University Ph.D. program in Chemical Engineering. 

职能部门领导人

Surendra Balekai

Vice President of Fluid Management

Surendra Balekai joined Repligen in January 2019 and was named Vice President, Fluid Management in January 2024. He previously served as Senior Director, Product Management, responsible for the Company’s tangential flow filtrations (TFF) and Chromatography Systems and related consumables. Prior to joining Repligen, Mr. Balekai was with Thermo Fisher Scientific for 12 years, most recently in global Product Management and Director roles focused on single-use bioprocessing equipment and consumables. While at Thermo Fisher Scientific, he successfully implemented regional growth strategies (Asia Pacific) and established field applications and services teams to support the bioproduction business. Earlier, Mr. Balekai was with Sartorius Stedim Biotech (eight years) as Business Manager, Purification and Single-Use Technologies, and with Millipore India (five years) as a Senior Process Specialist. Mr. Balekai earned a B.S. in Chemical Engineering from Ramaiah Institute of Technology, and a M.B.A. from Jack Welch Management Institute. He has also received a Certificate of Specialization in Strategy from Harvard Business School online.

Kimberly Cornwell

General Counsel

General Counsel

Leslie Galvin

Vice President, Human Resources

Leslie Galvin joined Repligen in May 2022 and currently serves as Vice President, Global Head, Human Resources, supporting the global operations function. Her responsibilities include human capital strategy, global talent acquisition, employee development, diversity & inclusion, and human resources (“HR”) operations. Ms. Galvin has over 20 years of global HR leadership experience in the life sciences, healthcare, and high-tech manufacturing industries. She earned a  B.S. in Human Resources and Industrial and Labor Relations from Bowling Green State University, and a M.S.A. in Human Resources from Central Michigan University. Ms. Galvin also holds a J.D. with a concentration in Employment Law from Capital University.

Kola Otitoju

Senior Vice President Strategy and Business Development and Global Head of Bioprocess Analytics

Kola Otitoju joined Repligen in 2020 and currently serves as Senior Vice President of Strategy and Business Development & Global Head of Bioprocess Analytics. Since 2020, he has been responsible for leading the development and execution of the Repligen growth strategy as related to key partnerships, licensing agreements, technology investments and mergers and acquisitions. By late 2022, Mr. Otitoju was also given the responsibility to lead the company’s Process Analytics Technology (“PAT”) business, where he oversees R&D, operations, quality and commercial activities, with a focus on expanding the PAT portfolio. Mr. Otitoju brings a wealth of experience in strategic planning and execution having over the course of 15-plus years been involved in private equity, investment banking and corporate deal-making. He led multiple transactions in excess of $100 billion through his tenures in Investment Banking M&A at Credit Suisse and Banc of America Securities, and through his experience at large publicly traded corporations including Baxter International and GE Healthcare (now Cytiva), as well as with private equity-backed companies including Candela Medical, while with Apax Partners. Earlier in his career, Mr. Otitoju was an electrical engineer. He holds a M.B.A. from Harvard Business School, a M.S. in Electrical Engineering from Cornell University, and a B.S. in Information Systems Engineering from Imperial College London.

Surendra Balekai joined Repligen in January 2019 and was named Vice President, Fluid Management in January 2024. He previously served as Senior Director, Product Management, responsible for the Company’s tangential flow filtrations (TFF) and Chromatography Systems and related consumables. Prior to joining Repligen, Mr. Balekai was with Thermo Fisher Scientific for 12 years, most recently in global Product Management and Director roles focused on single-use bioprocessing equipment and consumables. While at Thermo Fisher Scientific, he successfully implemented regional growth strategies (Asia Pacific) and established field applications and services teams to support the bioproduction business. Earlier, Mr. Balekai was with Sartorius Stedim Biotech (eight years) as Business Manager, Purification and Single-Use Technologies, and with Millipore India (five years) as a Senior Process Specialist. Mr. Balekai earned a B.S. in Chemical Engineering from Ramaiah Institute of Technology, and a M.B.A. from Jack Welch Management Institute. He has also received a Certificate of Specialization in Strategy from Harvard Business School online.

General Counsel

Leslie Galvin joined Repligen in May 2022 and currently serves as Vice President, Global Head, Human Resources, supporting the global operations function. Her responsibilities include human capital strategy, global talent acquisition, employee development, diversity & inclusion, and human resources (“HR”) operations. Ms. Galvin has over 20 years of global HR leadership experience in the life sciences, healthcare, and high-tech manufacturing industries. She earned a  B.S. in Human Resources and Industrial and Labor Relations from Bowling Green State University, and a M.S.A. in Human Resources from Central Michigan University. Ms. Galvin also holds a J.D. with a concentration in Employment Law from Capital University.

Kola Otitoju joined Repligen in 2020 and currently serves as Senior Vice President of Strategy and Business Development & Global Head of Bioprocess Analytics. Since 2020, he has been responsible for leading the development and execution of the Repligen growth strategy as related to key partnerships, licensing agreements, technology investments and mergers and acquisitions. By late 2022, Mr. Otitoju was also given the responsibility to lead the company’s Process Analytics Technology (“PAT”) business, where he oversees R&D, operations, quality and commercial activities, with a focus on expanding the PAT portfolio. Mr. Otitoju brings a wealth of experience in strategic planning and execution having over the course of 15-plus years been involved in private equity, investment banking and corporate deal-making. He led multiple transactions in excess of $100 billion through his tenures in Investment Banking M&A at Credit Suisse and Banc of America Securities, and through his experience at large publicly traded corporations including Baxter International and GE Healthcare (now Cytiva), as well as with private equity-backed companies including Candela Medical, while with Apax Partners. Earlier in his career, Mr. Otitoju was an electrical engineer. He holds a M.B.A. from Harvard Business School, a M.S. in Electrical Engineering from Cornell University, and a B.S. in Information Systems Engineering from Imperial College London.

Keith Lee Robinson

Chief Information Officer

Keith Lee Robinson joined Repligen in 2015 and currently serves as Chief Information Officer. He is responsible for enabling and optimizing business productivity, driving technological innovation, protecting the company’s digital assets and running an efficient IT organization. Prior to being named Chief Information officer, Mr. Robinson held numerous IT leadership roles at Repligen, building and leading the global IT organization; this includes the implementation worldwide of Enterprise Resource Planning, Customer Relationship Management, Quality Management, Business Intelligence solutions and cybersecurity processes and controls. A Jamaican native, he has accumulated over two decades of experience consulting on and managing information systems and information technology in multiple industries in the United States, Canada and the Caribbean. Mr. Robinson earned a M.S in Management Information Systems from the University of the West Indies, Jamaica.

Greg Titus

Senior Vice President, Commercial Development

Greg Titus joined Repligen in March 2023 and currently serves as Senior Vice President Commercial Development. Mr. Titus is responsible for developing and implementing Repligen’s corporate commercial strategy, as well as developing and leading top-down sales initiatives across the global commercial organization. He brings over 30 years of life sciences industry experience to Repligen, including development and leadership of bioprocessing commercial strategies and teams within the US and globally. Prior to joining Repligen, Mr. Titus spent a combined 13 years with Cytiva (a Danaher company and previously GE Healthcare Life Sciences), including his most recent role of General Manager, Global Strategic Accounts and Advanced Therapies. Prior to this, he led Key Account Management programs and Business Development for EMD Millipore (now Millipore Sigma), where he served for 17 years. Mr. Titus began his career in various service engineering, technical specialist and sales roles that led to more strategic and operational opportunities. He was raised and currently lives in Napa Valley California, and is the founder & winemaker of Ominous Cellars. Mr. Titus holds a B.S. in Electrical & Computer Engineering from Heald Institute of Technology, and negotiation-focused certificates from Harvard Business and El Camino College.

Neil Whitfield

副总裁,销售

Neil Whitfield joined Repligen in May 2020 and currently serves as Vice President, Global Sales & Support. Mr. Whitfield is responsible for building and developing a world class sales organization that executes effectively and delivers a positive customer experience. Prior to being named Vice President, Global Sales in October 2022, Mr. Whitfield served as Vice President, Commercial Development. Before joining Repligen, Mr. Whitfield was with Thermo Fisher Scientific where he led the commercial organization for the Bioproduction Division in EMEA for nine years and successfully integrated the commercial organizations of Life Technologies Inc. and Thermo Fisher Scientific into one cohesive team. Mr. Whitfield also spent 25 years at Applied Biosystems in various operational roles, before moving into the commercial organization to lead the Applied Markets Division in Europe and Middle East for Process Analytics, Food Pathogens and Animal Diagnostics. Mr. Whitfield holds a HNC. qualification in Chemistry from the University of Manchester, U.K. and a P.G.Dip. in Business Management from Liverpool University, U.K. 

Keith Lee Robinson joined Repligen in 2015 and currently serves as Chief Information Officer. He is responsible for enabling and optimizing business productivity, driving technological innovation, protecting the company’s digital assets and running an efficient IT organization. Prior to being named Chief Information officer, Mr. Robinson held numerous IT leadership roles at Repligen, building and leading the global IT organization; this includes the implementation worldwide of Enterprise Resource Planning, Customer Relationship Management, Quality Management, Business Intelligence solutions and cybersecurity processes and controls. A Jamaican native, he has accumulated over two decades of experience consulting on and managing information systems and information technology in multiple industries in the United States, Canada and the Caribbean. Mr. Robinson earned a M.S in Management Information Systems from the University of the West Indies, Jamaica.

Greg Titus joined Repligen in March 2023 and currently serves as Senior Vice President Commercial Development. Mr. Titus is responsible for developing and implementing Repligen’s corporate commercial strategy, as well as developing and leading top-down sales initiatives across the global commercial organization. He brings over 30 years of life sciences industry experience to Repligen, including development and leadership of bioprocessing commercial strategies and teams within the US and globally. Prior to joining Repligen, Mr. Titus spent a combined 13 years with Cytiva (a Danaher company and previously GE Healthcare Life Sciences), including his most recent role of General Manager, Global Strategic Accounts and Advanced Therapies. Prior to this, he led Key Account Management programs and Business Development for EMD Millipore (now Millipore Sigma), where he served for 17 years. Mr. Titus began his career in various service engineering, technical specialist and sales roles that led to more strategic and operational opportunities. He was raised and currently lives in Napa Valley California, and is the founder & winemaker of Ominous Cellars. Mr. Titus holds a B.S. in Electrical & Computer Engineering from Heald Institute of Technology, and negotiation-focused certificates from Harvard Business and El Camino College.

Neil Whitfield joined Repligen in May 2020 and currently serves as Vice President, Global Sales & Support. Mr. Whitfield is responsible for building and developing a world class sales organization that executes effectively and delivers a positive customer experience. Prior to being named Vice President, Global Sales in October 2022, Mr. Whitfield served as Vice President, Commercial Development. Before joining Repligen, Mr. Whitfield was with Thermo Fisher Scientific where he led the commercial organization for the Bioproduction Division in EMEA for nine years and successfully integrated the commercial organizations of Life Technologies Inc. and Thermo Fisher Scientific into one cohesive team. Mr. Whitfield also spent 25 years at Applied Biosystems in various operational roles, before moving into the commercial organization to lead the Applied Markets Division in Europe and Middle East for Process Analytics, Food Pathogens and Animal Diagnostics. Mr. Whitfield holds a HNC. qualification in Chemistry from the University of Manchester, U.K. and a P.G.Dip. in Business Management from Liverpool University, U.K. 

董事会

01

Chairperson

Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC (“Wyeth”), a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX® and Neumega®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol®/Glucotrol XL®, Zoloft®, and Cardura®. Ms. Dawes also serves on the board of directors of two publicly traded companies: Vaccitech Limited and Medicenna Therapeutics Corp, one private company, JPA Health, and one not-for-profit company, Medicines 360. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.

02

Nicolas M. Barthelemy has served as a director of Repligen since June 2014. Mr. Barthelemy brings over 30 years of industry experience to the director role. Mr. Barthelemy served as President and CEO of bioTheranostics, a molecular diagnostics company, from September 2014 until February 2017. Prior to bioTheranostics, he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen Inc. (“Biogen”) for eight years, most recently as Vice President, Manufacturing and General Manager for the company’s manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. Mr. Barthelemy also serves on the board of directors of three privately held companies: Biocare Medical LLC, NanoCellect Biomedical, and Slingshot Biosciences. He also serves as an advisor to Warburg Pincus, a private equity firm. Mr. Barthelemy previously served as a board member of Twist Bioscience, 908 Devices Inc. and Standard BioTools, Inc. (previously Fluidigm Corporation). Mr. Barthelemy received a M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles, Paris. Mr. Barthelemy’s qualifications to sit on the Company’s Board include his extensive experience in the bioprocessing field, including large scale biologics manufacturing and commercialization of consumables used in bioprocessing.

03

Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

04

Konstantin Konstantinov, Ph.D., has served as a director of Repligen since May 2022. He has also been a member of our Scientific Advisory Board since March 2016. Dr. Konstantinov is currently Chief Technology Officer at Codiak BioSciences (“Codiak”), where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. Before joining Codiak, Dr. Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.

08

Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus joins the Board with over 25 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation (“Millipore”), where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA (“Merck”) in 2010. He is an active board leader, currently serving two other public companies: as Lead Director for precision health technology company Quanterix Corporation and as a board member for mass cytometry player Standard BioTools, Inc. (previously Fluidigm Corporation). He also serves on the boards of three private companies: Unchained Labs, Emulate Inc. and Ultivue Inc. Dr. Madaus is currently a senior operating executive at The Carlyle Group (since 2019), a multinational private equity and asset management services company. He previously served as Chairman and CEO at Ortho-Clinical Diagnostics from 2014 to 2019. His tenure with biopharmaceutical and diagnostic industry leader Roche Holding AG (“Roche”) from 1996 to 2004 included his position from 2000 to 2004 as President and CEO, N.A. of Roche Diagnostics Corp. Dr. Madaus began his career as a veterinarian, before joining global pharmaceutical and diagnostic company Boehringer Mannheim Corporation (“Boehringer”). While at Boehringer, he held sales, marketing and product management roles from 1989 to 1996, until his move into general management coincided with the company’s acquisition by Roche in 1996. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany. Dr. Madaus’ qualifications to sit on the Company’s Board include his extensive bioprocessing and biopharmaceutical industry experience, especially in the areas of strategy, mergers and acquisitions, and commercial operations.

05

Carrie Eglinton Manner has served as a director of Repligen since June 2020. She brings to the director role over 25 years of leadership experience across multiple disciplines. Ms. Eglinton Manner currently serves as President and CEO of OraSure Technologies, Inc. (“OraSure”), which she joined in June 2022. OraSure is a leader in the development, manufacture and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular service solutions designed to discover and detect critical medical conditions. Prior to OraSure, Ms. Eglinton Manner served as Senior Vice President, Advanced & General Diagnostics and Clinical Solutions at Quest Diagnostics (“Quest”), which she joined in 2017. In her role at Quest, Ms. Eglinton Manner was responsible for value creation across the company’s $10 billion clinical portfolio, driving innovation in R&D, along with partnerships and acquisitions. She helped accelerate growth in Quest’s $2 billion Advanced Diagnostics portfolio, which included its specialty molecular and genetic offerings, along with Quest’s global and pharmaceutical services businesses. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. In addition to the Repligen Board, Ms. Eglinton Manner serves as board director for the not-for-profit Thrive Networks, focused on advancing women and building healthy, resilient communities. Ms. Eglinton Manner holds a B.S. in Mechanical Engineering from the University of Notre Dame. Ms. Eglinton Manner’s qualifications to sit on the Company’s Board include her track record of delivering business expansion and profitability for rapidly growing global businesses, including her experience with integrating acquisitions and building operations excellence, with a commitment to quality and process improvements.

06

Rohin Mhatre, Ph.D., was appointed to the Board in March 2020. Dr. Mhatre brings over 25 years of relevant experience to the director role, including his current position since January 2017, as Senior Vice President, Product and Technology Development at Biogen. He has held numerous other roles of increasing responsibility within Biogen, which he joined in 1996, including six years as Vice President of Biopharmaceutical Development, where he led a 300-member team responsible for cell line, cell culture, purification and device development. Earlier in Dr. Mhatre’s career at Biogen, he focused on building out analytical development and technical services. Prior to Biogen, Dr. Mhatre led the purification and applications group at Applied BioSystems (formerly Perspective Biosystems). Dr. Mhatre holds a Ph.D. in Chemistry from Northeastern University. Dr. Mhatre’s qualifications to sit on the Company’s Board include his extensive technical expertise, his leadership abilities and his deep understanding of the dependencies between biological drug development and efficient manufacturing workflows.

07

Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc. (“Hologic”), a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President. Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venture-backed single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984, he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir also serves on the board of directors of two publicly traded companies: medical technology company, Neuronetics, Inc., and life science company G1 Therapeutics, Inc., and one privately held company: medical device company Impulse Dynamics Limited. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant (inactive since 2022) with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S. from Bentley University and an M.B.A. from Harvard University. Mr. Muir’s qualifications to sit on Repligen’s Board include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization.

09

Maggie A. Pax has served as a director of Repligen since March 2024. Ms. Pax brings over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher, where, from 2016 to 2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business case for the company’s multi-billion acquisition of Patheon, a leading biopharmaceutical contract manufacturer. Ms. Pax’s background also includes her position as Senior Director, Corporate Development & Strategy at Thermo Fisher from 2013 to 2016, where she led post-merger commercial integration for the company’s acquisition of Life Technologies. Earlier in her career with Thermo Fisher, she was the Senior Director, Portable Analytical Instrumentation from 2012 to 2013.  From 1989 to 2000, Ms. Pax was with Phillips Healthcare (“Phillips”), a leading medical device company, where she held senior leadership roles in Business Development, Marketing and Product Management. Between her Phillips and Thermo Fisher roles, Ms. Pax held several entrepreneurial leadership positions, including as Vice President, Business and Clinical Development for five years (2006 to 2011) with Microchips Biomedical, an MIT startup company that was acquired by Daré Bioscience. Ms. Pax is currently an independent board director Alimera Sciences, a Nasdaq-listed pharmaceutical company, and Jellagen, a privately-held UK company. She also sits on the board of the U.S. subsidiary of BioPorto A/S, a Danish-based kidney biomarker company. Ms. Pax advises a range of healthcare and life sciences companies on business strategy, commercial growth, and partnerships.  She holds a B.A. from the College of Holy Cross, and an M.B.A. from Harvard Business School, where she currently serves as a board member of the Harvard Business School Healthcare Alumni Association.

科学顾问委员会

01

Richard D. Braatz是麻省理工学院(MIT)的Edwin R. Gilliland教授,他在工艺数据分析、设计和先进制造系统的控制方面进行研究。他拥有加利福尼亚理工学院硕士学位和博士学位,曾是伊利诺伊大学厄本那-香槟分校的千年主席和教授,在加入麻省理工学院之前,他是哈佛大学的访问学者。他已经与超过30家公司进行了咨询和/或合作,其中包括默克、诺华、辉瑞、安进、百健和百时美施贵宝。他是美国国家工程院院士。

02

Charles L. Cooney是麻省理工学院化学工程系荣誉退休教授罗伯特·哈斯拉姆(1911)化学和生化工程教授,也是麻省理工学院Deshpande技术创新中心荣誉退休教授。他拥有宾夕法尼亚大学化学工程学士学位以及麻省理工学院的生物化学工程硕士和博士学位。他曾在麻省理工学院任教。他是工艺设计、上游和下游生物工艺开发以及制药和生物制品生产方面的专家。Cooney教授曾担任多家生物技术和制药公司的顾问或董事会成员,并且是Repligen科学顾问委员会主席。

03

Cramer博士是伦斯勒理工学院的William Weightman Walker教授,并以其对复杂生物制品的分离以及层析材料、工艺和可用于其生物制造的预测工具的开发所做出的贡献而闻名。此外,他对分子间相互作用的理解做出了开创性的贡献,这些相互作用在这些分离系统中产生了独特的选择性。他的实验室目前正在与蛋白质-表面相互作用相关的几个领域进行研究,包括蛋白质结合亲和性的预测和层析系统的多维度建模、高效抗体和双特异性抗体分离系统的开发、多峰色谱的基础研究、多级自动肽合成/筛选亲和肽设计系统、智能生物聚合物亲和沉淀系统、蛋白质与表面、配体和蛋白质相互作用的生物物理学、有效去除工艺HCP的平台化策略以及集成的半连续生物生产工艺。他已担任《分离科学与技术》的编辑20年,曾获得Alan S. Michaels生物制品回收奖(生化技术ACS部)和ACS国家分离科学与技术奖。他还获得了伦斯勒杰出教授奖以及工程学院杰出教授和卓越研究奖。Cramer博士当选为美国科学促进协会、美国化学工程师学会、美国化学学会和美国医学与生物工程学会的研究员。

05

Konstantin Konstantinov, Ph.D., has been a member of our Scientific Advisory Board since March 2016. He also serves as a director of Repligen since May 2022. Dr. Konstantinov is currently Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.

06

J. Christopher Love是Raymond A.(1921)和Helen E. St. Laurent化学工程教授,也是麻省理工学院科赫综合癌症研究所的成员。此外,他还是Eli和Edythe L. Broad研究所以及MGH Ragon研究所、MIT和哈佛的准成员。Love教授于2004年获得哈佛大学物理化学博士学位。他于2004年-2005年在哈佛医学院及2005年-2007年在免疫疾病研究所将其研究扩展到了免疫学领域。他的研究集中在使用简单的微系统来监测慢性人类疾病临床样本中的细胞,以及开发新方法,用于生产高效且负担得起的生物药和疫苗。Love教授在2009年被评为Dana人类免疫学学者,并被授予Keck杰出青年医学研究学者,在2010年被评为科普杰出人才10之一,并被Camille Dreyfus授予教师奖学金。在麻省理工学院,他是替代宿主协会主席,其是麻省理工学院与工业界独特的合作,致力于推动生物制药和疫苗的新生产宿主的发展。他之前曾在Biogen(2015-2016)担任驻地杰出工程师,还为多家生物技术和生物制药公司提供咨询服务,包括三家基于他在麻省理工学院实验室所开发的技术的初创公司(Honeycomb、OneCyte和Sunflower)。

07

Hubert Scoble’s, Ph.D., professional career spans four decades in the biotechnology and biopharmaceutical industry. The majority of his career has focused on drug substance and drug product biopharmaceutical development and clinical and commercial production operations with Genetics Institute, Wyeth, Pfizer and Sanofi. He has had responsibility for all aspects of pre- and post-approval CMC biopharma drug development, technical portfolio management and product and technical strategy development and deployment. Throughout his career he has been directly involved with the regulatory approval of 20+ commercial biopharma products.

Dr. Scoble received his Ph.D. in Analytical Chemistry from the University of Rhode Island which was followed by a Postdoctoral Fellowship in the Department of Chemistry at MIT (K. Biemann laboratory). He currently serves as a CMC, technical and operational strategy consultant to large and smaller biopharmaceutical companies and also serves on the Scientific/Technical Advisory Boards for several companies.